Trials / Completed
CompletedNCT01922193
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 263 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Highly Purified Urofollitropin | for injection |
| DRUG | Recombinant Human Follitropin Alfa | for injection |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-02-01
- Completion
- 2015-04-01
- First posted
- 2013-08-14
- Last updated
- 2015-06-16
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01922193. Inclusion in this directory is not an endorsement.